Sai Parenteral's Limited IPO

Mainboard

Pharmaceuticals

Listed On: Apr 2, 2026 at ₹ 400.0(NSE)

₹ 14896 /38 Shares
Minimum Investment

Check Allotment

24 Mar, 2026

Open Date

27 Mar, 2026

Close Date

30 Mar, 2026

Allotment Date

02 Apr, 2026

Listing Date

Price Summary

Last Closing

483.00 (23.21%)

52 Week High

526.30

52 Week Low

400.00

Last Update

17-Apr-2026 3:30 PM

Sai Parenteral's IPO Live Subscription Details

View Subscription Details

QIB 1.73x

Retail 0.12x

NIIs 2.45x

BHNI 3.56x

SHNI 0.24x

Retail 0.12x

Total 1.08x

Last updated: 27 Mar 2026, 05:54 PM

Sai Parenteral's IPO Issue Details

Issue Price ₹372-392 per equity share
Face Value ₹5 Per Equity Share
Total Issue Size 1,04,28,288 shares(aggregating up to ₹408.79 crore)
Fresh Share 72,70,408 shares(aggregating up to ₹285 crore)
Offer For Sale 31,57,880 shares(aggregating up to ₹123.79 crore)
Listing at BSE, NSE
List Price 400.0(NSE)
Listing Date 2026-04-02
Lead Manager Arihant Capital Markets Ltd.
Registrar Bigshare Services Pvt.Ltd.

Market Lot Size

Investors can bid for a minimum of 38 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Retail Investors and HNI in terms of shares and amount.

Application	Lots	Shares	Amount
Retail (min)	1	38	₹14,896
Retail(max)	13	494	₹1,93,648
SHNI(min)	14	532	₹2,08,544
SHNI(max)	67	2,546	₹9,98,032
BHNI(min)	68	2,584	₹10,12,928

Sai Parenteral's IPO Reservation

Sai Parenteral's IPO offers total 10428288 shares. Out of which 2085659 (20%) allocated to QIB, 1564243 (15%) allocated to NII,3649901 (35%) allocated to RII, NA (NA%) allocated to employees and 3128485 (30%) allocated to Anchor investors.

Investor Category	Shares Offered	Maximum Allottees
Anchor Investor Shares Offered	3128485 (30%)
QIB Shares Offered	2085659 (20%)
NII (HNI) Shares Offered	1564243 (15%)
bNII > ₹10L	1042829 (10%)
sNII < ₹10L	521414 (5%)
Retail Shares Offered	3649901 (35%)
Total Shares Offered	10428288 (100%)

Sai Parenteral's IPO Documents

DRHP

RHP

ANCHOR

Sai Parenteral's IPO Details

Sai Parenteral's IPO is a book-built issue of ₹408.79 crores, The total issue size is ₹408.79 crores. The IPO of Sai Parenteral's is priced at ₹372-392 per equity share, which has a face value of ₹5 Per Equity Share each, IPO bidding starts from Mar 24, 2026 and ends on Mar 27, 2026. The allotment for Sai Parenteral's IPO will be finalized on Mar 30, 2026. Sai Parenteral's IPO will be listed on BSE, NSE, with a tentative listing date fixed as Apr 2, 2026. The company shall list its equity shares on the BSE, NSE. Bigshare Services Pvt.Ltd. is the registrar of the issue.

Retail investors can bid for a minimum of 38 shares, extendable to 14,896. S-HNIs will be able to bid for 532 shares at ₹2,08,544, while B-HNIs can also apply for a bid of 2,584 shares at ₹10,12,928. The book-running lead manager for the IPO is/are Arihant Capital Markets Ltd..

The total issue ₹408.79 crore, comprising a fresh issue of 72,70,408 shares ₹285 crore and having Offer for Sale (OFS) of 31,57,880 shares to mop up ₹123.79 crore.

The Sai Parenteral's IPO sets its price band at 372-392 for each share. A single application for Sai Parenteral's Limited IPO must contain at least 38 shares. Sentiment investors need to invest a minimum of 38 through their retail account. For investors to prevent oversubscription issues, they should submit bids at the cutoff price, which estimates about ₹14,896 In order to participate in the sNII, investors must purchase at least 14 lots of 532 shares for ₹2,08,544, while the bNII requires 68 lots of 2,584 shares for an investment of ₹10,12,928.

As on	QIB	NII bNII sNII	Retail	Total
Shares Offered / Reserved	20,85,659	15,64,243 10,42,829 5,21,414	36,49,901	72,99,803
Day 1 24-03-26 05:00 PM	0.00 x	0.15 x 0.22 x 0.03 x	0.03 x	0.05 x
Day 2 25-03-26 05:00 PM	0.60 x	1.05 x 1.55 x 0.04 x	0.05 x	0.42 x
Day 3 27-03-26 05:00 PM	1.73 x	2.45 x 3.56 x 0.24 x	0.12 x	1.08 x

Total No of Applications

8,166

Subscription on the basis of Applications

Retail:0.08x BHNI:0.08x SHNI:0.13x

Sai Parenteral's Valuations

EPS Pre IPO ₹5.43/-

EPS Post IPO ₹/-

P/E Pre IPO 72.19

ROE 16.82%

ROCE 28.92%

RoNW 15.09%

PAT Margin 8.88%

Price to Book Value 10.89

Market Cap. 1,731.83 Cr.

Sai Parenteral's Company Financials

In Crs.

In Cr.

	30-Sep-25	31-Mar-25	31-Mar-24	31-Mar-23
Assets	376.24	272.39	268.10	133.96
Revenue	89.43	163.74	155.18	97.03
Profit After Tax	7.76	14.43	8.42	4.38
Net Worth	209.37	95.78	76.40	31.49
Reserves & Surplus	188.84	80.36	61.30	24.34
Total Borrowing	76.07	93.95	118.79	68.55

About Sai Parenteral's Company

Established in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research and development and manufacturing.
The company has two business segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) products and services.
The company’s product portfolio covers a wide spectrum of pharmaceutical formulations in various therapeutic areas such as cardiovascular, neuropsychiatry, anti-diabetic agents, respiratory health, antibiotics, gastroenterology, vitamins, minerals, and supplements (VMS), analgesics, and dermatology in various dosage forms such as injectables, tablets, capsules, liquid orals, and ointments.
The company’s customer base comprises central and state government departments, pharmaceutical companies, public and private sector hospitals, and super stockists across India. Sai Parenteral’s started its export business in FY 2023 after acquiring two international accredited facilities in Hyderabad, Telangana, and currently serves regulated and semi-regulated markets such as Australia, New Zealand, Southeast Asia, Middle East, and Africa.

The company has five manufacturing facilities in India. Four are located in Hyderabad, Telangana. These are a GMP compliant injectable facility, a WHO-GMP injectable facility, a TGA-Australia and PIC/S accredited solid oral dosage facility, and a WHO-GMP cephalosporin facility. The company’s wholly owned subsidiary has a GMP certified facility located in Ongole, Andhra Pradesh.
As of August 31, 2025, Sai Parenteral's Ltd. had 277 full-time employees.

Sai Parenteral's - Promoter(s)

Anil Kumar Karusala

Vijitha Gorrepati

Karusala Aruna

Pre Issue Share Holding : N/A%

Post Issue Share Holding : N/A%

Sai Parenteral's IPO - Issue Objectives

Capacity expansion and upgradation of manufacturing facilities - ₹110.80 Crores

Establishment of a new R&D Centre - ₹18.02 Crores

Repayment / prepayment of certain outstanding borrowings - ₹14.30 Crores

Working capital requirements - ₹33.00 Crores

Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia) - ₹35.64 Crores

General corporate purposes

Sai Parenteral's IPO - Anchor Investors

Sai Parenterals raises Rs 123 crore via anchor book ahead of IPO.
Out of the total allocation, 9.18 lakh shares worth Rs 36 crore were allocated to one domestic mutual fund, namely Quant Mutual Fund, and 7.65 lakh shares worth Rs 30 crore to one insurance company, namely Kotak Mahindra Life Insurance Company.
Kotak Life Sciences Fund also subscribed to 7.65 lakh shares worth nearly Rs 30 crore, followed by Morgan Stanley Asia (Singapore), and India Emerging Giants Fund, which acquired 3.82 lakh shares worth Rs 15 crore and 2.96 lakh shares worth Rs 11.63 crore, respectively.

Strength

Diversified formulation portfolio with an excellent track record: The company has an established presence across several therapeutic segments and dosage forms, thus minimizing dependence on a single product category.

Strategically positioned and accredited manufacturing facilities: The WHO-GMP and international accreditations such as TGA and PIC/S for manufacturing facilities enhance credibility and provide access to regulated export markets.

Strong focus on CDMO business: The company’s CDMO business offers an opportunity for long-term contracts and high margins.

Weakness

Geographical concentration of manufacturing facilities: The company’s manufacturing facilities are concentrated mainly in Telangana and Andhra Pradesh states. This creates risks of disruptions or changes in regional regulations.

Dependence on Injectable Segment: The company derives significant revenue from the Injectable Segment. Hence, it is highly vulnerable to fluctuations in demand for products from this segment.

Regulatory compliance risk: The company’s manufacturing facilities are subject to inspections and audits. Adverse observations during inspections and audits may affect business.

Contact Details

Sai Parenteral's

Plot No 39, 5th Floor, Lavanya Arcade, Jayabheri Enclave, Gachibowli, K.V. Rangareddy, Seri Lingampally, Hyderabad, Telangana - 500032.

+91 79979 91301

cs@saiparenterals.com

https://saiparenterals.com

Registrar Contact Details

Bigshare Services Pvt Ltd

+91-22-6263 8200

ipo@bigshareonline.com

https://ipo.bigshareonline.com/ipo_status.html

Sai Parenteral's IPO - FAQs

Ans. Sai Parenteral's Limited IPO is a Mainboard IPO. The issue is priced at ₹372-392 per equity share. The minimum order quantity is 38 Shares. The IPO opens on Mar 24, 2026, and closes on Mar 27, 2026. Bigshare Services Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.

Ans. The Sai Parenteral's Limited IPO opens on Mar 24, 2026 and closes on Mar 27, 2026.

Ans. You can track the real-time subscription numbers using the links below:

Ans. The size of Sai Parenteral's Limited IPO is ₹408.79 Crores.

Ans. The Sai Parenteral's Limited IPO price band is set between ₹372-392 per equity share.

Ans. To apply for Sai Parenteral's Limited IPO, follow the steps given below:

- Open the IPO Ji App or Website
- Find Sai Parenteral's Limited IPO in the List of IPOs
- Press Apply Button
- Select Your Demat Account
- Select Your Shares Quantity and Submit
- Track Your IPO Status

Ans. The share allotment date of Sai Parenteral's Limited IPO is Mar 30, 2026.

Ans. The Sai Parenteral's Limited IPO will be listed on Apr 2, 2026.

Ans. Follow the steps to check the Sai Parenteral's Limited IPO allotment status online.